Introducing Ro’s GLP-1 Pipeline Tracker
Your (our!) solution to keeping up with the ever-growing obesity drug universe, including key players, trials, and results.
The obesity drug pipeline is moving fast and getting increasingly crowded. With each passing day, it’s becoming more difficult to keep track of the players, drugs, trials, and outcomes. To solve this problem, we’ve created the Ro GLP-1 Pipeline Tracker to help us stay on top of it all, and we want to share it with you.
You can search by company, drug, or drug type (e.g., GLP-1, GLP-1/GIP, amylin). There’s a timeline view to help track where drugs are in the clinical development process.
You can also explore key data points, such as trial efficacy readouts, along with other handy information, such as participant demographics and adverse events. There’s also a tab that allows you to “compare” trial results.
Of course, as a rule, different trials are not directly comparable. But even though it’s naughty, sometimes there’s practical utility in seeing results next to each other.
We’re only using publicly available information (i.e., press releases, published papers, clinicaltrials.gov), and we will do our best to keep it updated as time goes on!
Give us a shout on X — let us know how you are using the tracker and if you have feedback.